Proprietary AI analyst is now available
- Public Comps
- Abingdon Health
Abingdon Health Valuation Multiples
Discover Abingdon Health's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Mentice, Accuray, Diagnostic Medical Systems, Nutriband and more.
Abingdon Health Overview
About Abingdon Health
Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world.
Founded
2008
HQ

Employees
121
Website
Financials (LTM)
EV
$34M
Valuation Multiples
Start free trialAbingdon Health Financials
Abingdon Health reported last 12-month revenue of $16M and negative EBITDA of ($1M).
In the same LTM period, Abingdon Health generated $8M in gross profit, ($1M) in EBITDA losses, and had net loss of ($3M).
Revenue (LTM)
Abingdon Health P&L
In the most recent fiscal year, Abingdon Health reported revenue of $11M and EBITDA of ($3M).
Abingdon Health is unprofitable as of last fiscal year, with gross margin of 44%, EBITDA margin of (31%), and net margin of (40%).
Financial data powered by Morningstar, Inc.
Abingdon Health Stock Performance
Abingdon Health has current market cap of $37M, and enterprise value of $34M.
Market Cap Evolution
Abingdon Health's stock price is $0.15.
Abingdon Health share price decreased by 8.0% in the last 30 days.
Abingdon Health has an EPS (earnings per share) of $-0.02.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $34M | $37M | -0.5% | -8.0% | - | - | $-0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAbingdon Health Valuation Multiples
Abingdon Health trades at 2.1x EV/Revenue multiple, and (24.6x) EV/EBITDA.
EV / Revenue (LTM)
Abingdon Health Financial Valuation Multiples
As of June 23, 2026, Abingdon Health has market cap of $37M and EV of $34M.
Abingdon Health has a P/E ratio of (13.5x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Abingdon Health Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Abingdon Health Margins & Growth Rates
Abingdon Health grew revenue by 45% but EBITDA decreased by 61% in the last fiscal year.
In the most recent fiscal year, Abingdon Health reported gross margin of 44%, EBITDA margin of (31%), and net margin of (40%).
Abingdon Health Margins
Abingdon Health Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Abingdon Health Operational KPIs
Abingdon Health's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Abingdon Health's Rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Abingdon Health's Rule of X is 82% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Abingdon Health Competitors
Abingdon Health competitors include Mentice, Accuray, Diagnostic Medical Systems, Nutriband, Cryosite, SciBase Holding, TELA Bio, HeartBeam, Q-linea and Luna Innovations.
Most Abingdon Health public comparables operate across Diagnostics & Genomics, Medical Devices, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.1x | 1.0x | 72.0x | 23.7x | |||
| 0.4x | 0.4x | 6.4x | 119.3x | |||
| 0.8x | 0.8x | 9.2x | 8.4x | |||
| 12.5x | 12.5x | (4.2x) | - | |||
| 4.1x | - | 17.0x | - | |||
| 7.8x | 6.1x | (3.9x) | (4.2x) | |||
| 0.7x | 0.6x | (1.7x) | (1.8x) | |||
| - | 80.3x | (1.8x) | - | |||
This data is available for Pro users. Sign up to see all Abingdon Health competitors and their valuation data. Start Free Trial | ||||||
Abingdon Health VC Funding History
Before going public, Abingdon Health raised $14M in total equity funding, across 4 rounds.
Last private valuation of Abingdon Health was $14M, after raising $4M in July 2016 from Imperial Innovations.
Abingdon Health Funding Rounds
Acquisitions by Abingdon Health
Abingdon Health has acquired 4 companies to date.
Last acquisition by Abingdon Health was on July 25th 2024. Abingdon Health acquired Compliance Solutions for $4M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Abingdon Health
| Description | Compliance Solutions is a life sciences consultancy specializing in quality management systems, risk assessments, and regulatory submissions for medical devices and pharmaceuticals. The California-based firm supports ISO 13485 audits, FDA 483 responses, and EU MDR transitions through CAPA management and validation services. | - | Molecular Vision is a London-based optical detection company offering portable diagnostic devices using organic LEDs and photodetectors. Founded in 2001, its platform enables point-of-care fluorescence assays for biomarkers in blood and saliva. Applications extend to veterinary diagnostics, food safety testing for pathogens, and environmental monitoring of pollutants in field conditions. | Serascience is a UK-based diagnostic company developing assays for B-cell malignancies like multiple myeloma. Established in 2011, it supplies over 50 monoclonal antibodies specific to immunoglobulin classes and subclasses for applications in flow cytometry, ELISA, and immunohistochemistry. The Oxford facility produces reagents used by research labs worldwide, including heavy/light chain pairings for minimal residual disease monitoring. Serascience collaborates with NHS trusts on prognostic tools enhancing patient stratification in clinical trials. |
| HQ Country | ||||
| HQ City | - | - | London | Nottingham |
| Deal Date | 25 Jul 2024 | 7 May 2024 | 8 Jan 2015 | 24 Oct 2014 |
| Valuation | $4M | $1M | undisclosed | undisclosed |
| EV/Revenue | ||||
| EV/EBITDA | ||||
This data is available for Pro users. Sign up to see all Abingdon Health acquisitions and their M&A valuation multiples. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Abingdon Health
| When was Abingdon Health founded? | Abingdon Health was founded in 2008. |
| Where is Abingdon Health headquartered? | Abingdon Health is headquartered in United Kingdom. |
| How many employees does Abingdon Health have? | As of today, Abingdon Health has over 121 employees. |
| Is Abingdon Health publicly listed? | Yes, Abingdon Health is a public company listed on London Stock Exchange. |
| What is the stock symbol of Abingdon Health? | Abingdon Health trades under ABDX ticker. |
| When did Abingdon Health go public? | Abingdon Health went public in 2020. |
| Who are competitors of Abingdon Health? | Abingdon Health main competitors include Mentice, Accuray, Diagnostic Medical Systems, Nutriband, Cryosite, SciBase Holding, TELA Bio, HeartBeam, Q-linea, Luna Innovations. |
| What is the current market cap of Abingdon Health? | Abingdon Health's current market cap is $37M. |
| What is the current revenue of Abingdon Health? | Abingdon Health's last 12 months revenue is $16M. |
| What is the current revenue growth of Abingdon Health? | Abingdon Health revenue growth (NTM/LTM) is 25%. |
| What is the current EV/Revenue multiple of Abingdon Health? | Current revenue multiple of Abingdon Health is 2.1x. |
| Is Abingdon Health profitable? | No, Abingdon Health is not profitable. |
| What is the current EBITDA of Abingdon Health? | Abingdon Health has negative EBITDA and is not profitable. |
| What is Abingdon Health's EBITDA margin? | Abingdon Health's last 12 months EBITDA margin is (8%). |
| What is the current EV/EBITDA multiple of Abingdon Health? | Current EBITDA multiple of Abingdon Health is (24.6x). |
| How many companies Abingdon Health has acquired to date? | As of June 2026, Abingdon Health has acquired 4 companies. |
| What was the largest acquisition by Abingdon Health? | $4M acquisition of Compliance Solutions on 25th July 2024 was the largest M&A Abingdon Health has done to date. |
| What companies Abingdon Health acquired? | Abingdon Health acquired Compliance Solutions, IVDeology, Serascience, and Molecular Vision. |
| In how many companies Abingdon Health has invested to date? | Abingdon Health hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Abingdon Health
Lists including Abingdon Health
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

